Click on headlines below to download research
ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted…
The key news in the FY21 results statement was the restart of the Phase IIa (2m cell dose) extension study after a June safety halt due to a presumed intraocular…
There has been a safety halt to the lead human retinal progenitor cell (hRPC) project. The issue was an eye infection in one patient following a successful…